Loading patent…
OwnerNapoleone Ferrara, Colin Watanabe +1inventors
InventorsNapoleone Ferrara, Colin Watanabe, William I. Wood
Estimating the term…
The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
A composition of matter comprising (a) an EG-VEGF polypeptide, (b) an agonist of an EG-VEGF polypeptide, or (c) an antagonist of an EG-VEGF polypeptide, in admixture with a pharmaceutically acceptable carrier.
An article of manufacture, comprising:
A method for identifying a compound that binds to EG-VEGF comprising:
A method for identifying a compound that modulates a biological activity of EG-VEGF, comprising the steps of:
A method of identifying a receptor for EG-VEGF, said method comprising combining EG-VEGF with a composition comprising cell membrane material wherein said EG-VEGF complexes with a receptor on said cell membrane material, and identifying said receptor as a EG-VEGF receptor.
A method of inducing cell proliferation, comprising contacting said cells with EG-VEGF in an amount effective to induce proliferation of said cells.
A method of inducing cell proliferation, said method comprising introducing a nucleic acid encoding EG-VEGF into said cells in an amount effective to induce cell proliferation.
A method of inducing chemotaxis in cells, comprising contacting said cells with EG-VEGF in an amount effective to induce chemotaxis.
A method of inducing chemotaxis in cells, said method comprising introducing a nucleic acid encoding EG-VEGF into said cells in an amount effective to induce chemotaxis.
A method of treating an individual for a condition associated with hormone producing tissue, said method comprising administering to said individual a composition comprising EG-VEGF or an agonist or antagonist thereof in an amount effective to treat said condition.
A method of treating an individual for a condition associated with hormone producing tissue, said method comprising administering to said individual a composition comprising a nucleic acid encoding EG-VEGF or an agonist or antagonist thereof in an amount effective to treat said condition.
A method of inducing angiogenesis in hormone producing tissue, comprising contacting said tissue with EG-VEGF or an agonist thereof in an amount effective to induce angiogenesis.
A method of inducing angiogenesis in hormone producing tissue, said method comprising introducing a nucleic acid molecule encoding EG-VEGF or an agonist thereof into said hormone producing tissue in an amount effective to induce angiogenesis.
A method of inducing cell differentiation in cells, comprising contacting said cells with EG-VEGF or an agonist thereof in an amount effective to induce cell differentiation.
A method of inducing cell differentiation in cells, comprising introducing a nucleic acid molecule encoding EG-VEGF into said cells in an amount effective to induce cell differentiation.
A method of inducing fenestration in cells, contacting said cells with EG-VEGF or an agonist thereof in an amount effective to induce fenestration.
A method of inducing fenestration in cells, comprising introducing a nucleic acid molecule encoding EG-VEGF or an agonist thereof into said cells in an amount effective to induce fenestration.
A method of inhibiting endothelial cell proliferation, comprising contacting said cells with an EG-VEGF antagonist in an amount effective to inhibit cell proliferation.
A method of inhibiting chemotaxis in endothelial cells, comprising contacting said cells with an EG-VEGF antagonist in an amount effective to inhibit chemotaxis.
A method of inhibiting angiogenesis in hormone producing tissue, comprising contacting said tissue with an EG-VEGF antagonist in an amount effective to inhibit angiogenesis.
A method of inhibiting differentiation of cells, comprising contacting said cells with an EG-VEGF antagonist in an amount effective to inhibit cell differentiation.
A method of regulating fertility in an individual, comprising administering an EG-VEGF antagonist to said individual in an amount effective to regulate fertility.
A method of treating cancer in cells responsive to EG-VEGF in an individual, said method comprising administering an EG-VEGF antagonist to said individual in an amount effective to treat cancer.
A method of treating cancer of the reproductive organs in an individual, comprising administering an EG-VEGF antagonist to said individual in an amount effective to inhibit cancer.
A method of treating an ovarian cyst in an individual, comprising administering an EG-VEGF antagonist to said individual in an amount effective to inhibit growth of a cyst.
A method of regulating permeability of an endothelial cell comprising contacting said endothelial cell with an effective amount of EG-VEGF.
Dependencies are inferred from the claim text.